Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fusion protein, preparation method thereof, DNA sequence for coding protein, expression vector, host cell and protein-containing medicinal compoisition

A technology of DNA sequence and fusion protein, which is applied in the field of medicine, can solve problems such as the absence of IgG immunoglobulins, and achieve the effects of small dosage, high expression and low cost in clinical use

Active Publication Date: 2011-05-25
SHENZHEN TAILI BIOTECHNOLOGY CO LTD
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] However, there are no reports about the use of IgG class immunoglobulins in Exendin-4 to improve its half-life in vivo

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein, preparation method thereof, DNA sequence for coding protein, expression vector, host cell and protein-containing medicinal compoisition
  • Fusion protein, preparation method thereof, DNA sequence for coding protein, expression vector, host cell and protein-containing medicinal compoisition
  • Fusion protein, preparation method thereof, DNA sequence for coding protein, expression vector, host cell and protein-containing medicinal compoisition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Example 1 Preparation of Exendin-4 target gene and human IgG2 Fc fragment gene linked with linking peptide

[0064] The gene of the target protein containing signal peptide, Exendin-4 and G5S connecting peptide (synthesized by Shanghai Shenggong Co., Ltd.) is obtained by the method of whole gene synthesis, its nucleotide sequence is shown in SEQ ID NO: 7, and the amino acid sequence is shown in SEQ ID NO: 8 shown. Wherein, the 5' end of the nucleotide sequence contains a human I1-2 signal peptide sequence, and the 3' end contains a G5S linking peptide sequence for linking with the human IgG2 Fc fragment. In order to facilitate insertion into the cloning vector pCR2.1 (Invitrogen), a Kpn I restriction site was designed at the 5' end, and a BamH I restriction site was designed at the 3' end.

[0065] The following primers were designed to amplify the human IgG2 Fc fragment cDNA:

[0066] 5' Primer: 5'CG G GAT CC G AGC GCA AAT GTT GTG TCGAGT GC 3’

[0067] 3' Primer: ...

Embodiment 2

[0073] Example 2 Construction of recombinant plasmids

[0074] As mentioned above, a Kpn I restriction site is designed at the 5' end of the target gene, and a BamH I restriction site is designed at the 3' end, so that the target gene fragment can be directly inserted into the multiple cloning site Kpn I of the cloning vector pCR2.1 / BamH I, and then insert the human IgG2 Fc fragment into the multiple cloning site BamH I / EcoR I to obtain the Ex-4-Fc fusion fragment. A point mutation of the human IgG2 Fc fragment was carried out in the recombinant clone, and after sequencing and identification, Kpn I / EcoR I was used to insert the eukaryotic expression vector pAAV2-neo. The expression vector pAAV2-neo was transformed on the basis of pcDNA3.1 (Invitrogen), and the terminal repeat sequence of AAV2 was added to increase the stability of the integrated fragment in the genome (see image 3 ). The construction process of the recombinant plasmid is detailed in figure 1 .

[0075] 1...

Embodiment 3

[0083] Example 3 Screening and Identification of CHO Stable Expression Strains (E4F / CHO Cells)

[0084] 10 μg of the pEx-4-mFc plasmid prepared in Example 2 was used to transfect CHO-K1 cells (ATCC) with liposome Lipofectamine 2000 (Invitrogen). Two days later, the cells were subcultured at a ratio of 1:5, and 0.4 mg / ml G418 (Invitrogen) was added for selection. Colonies could be formed after 10 days. Digest 120 single clones with clear edges and good cell state and inoculate five 24-well plates at 37°C, 5% CO 2 Culture in an incubator (the first round of selection), the medium is DMEM / F12 (Invitrogen) containing 10% fetal bovine serum. Unless otherwise specified, the culture temperature and medium in the culture described below were the same as that.

[0085] The culture supernatant after three days was taken to detect the expression of the fusion protein by ELISA method, and 46 clones with positive expression were selected and inoculated in two 24-well plates respectively ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a fusion protein. The fusion protein sequentially contains exendin-4, a connecting peptide and a human IgG2 Fc mutant from an N end to a C end. The invention also relates to a preparation method for the fusion protein. The fusion protein can be highly expressed in a mannalian cell, and a purification process is simple and favorable for further preparing the fusion proteins in large scale. The fusion protein provided by the invention has the bioactivity of natural exendin-4 and the advantage of longer serum half-life period, and can stimulate the secretion of insulin, suppress the release of glucagons after food intake and be used for treating various diabete.

Description

technical field [0001] The present invention relates to the field of medicine, in particular, the present invention relates to a fusion protein containing insulin secretory hormone and its preparation method, a DNA sequence encoding the fusion protein, an expression vector containing the DNA sequence, and a host containing the expression vector Cells, and pharmaceutical compositions containing the fusion protein. Background technique [0002] Diabetes mellitus is a common metabolic endocrine disease, and its basic pathology is metabolic disorder caused by absolute or relative insulin secretion deficiency and glucagon activity increase. Diabetes is mainly divided into four types: insulin-dependent (type I) diabetes, non-insulin-dependent (type II) diabetes, malnutrition-related diabetes and secondary diabetes, of which type II diabetes accounts for more than 90%. The pathogenesis of type II diabetes is mainly insulin resistance with insulin secretion defect or insulin secret...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00C12N15/62C12N15/63C12N15/85C12N5/10C12P21/04C07K1/22C07K1/18C07K1/16A61K38/22A61P3/10
Inventor 韩为跃何凯阳勇杨立明叶学君闻亚磊张仁怀汪猜
Owner SHENZHEN TAILI BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com